RxDoctor Payments Data

Mitzilene Tuazon, MD

Family Medicine · Las Vegas, NVNPI 1528402351

Payments from drug & device makers

$732in general payments, 2019–2025

Across 45 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$195
  • Novo Nordisk$192
  • AstraZeneca$120
  • Pfizer$42
  • Teva Pharmaceuticals USA, Inc.$34
  • Amgen$32
  • plus $118 from 6 others

What the payments were for

  • Food & beverage$732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$732 in reported general payments places this provider in the 60th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$9,383
Medicare patients
51
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$177,745
MounjaroTirzepatide125$145,279
EliquisApixaban53$69,378
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$33,974
SynjardyEmpagliflozin/Metformin Hcl13$26,586
TrulicityDulaglutide18$22,778
XareltoRivaroxaban27$22,634
Synjardy XrEmpagliflozin/Metformin Hcl11$18,543
SymbicortBudesonide/Formoterol Fumarate53$12,460
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen252$9,817
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$9,393
Atorvastatin Calcium1,038$9,080
Omeprazole359$8,908
Arnuity ElliptaFluticasone Furoate25$7,063
Albuterol Sulfate HfaAlbuterol Sulfate212$5,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$192$177,745141 claims
PfizerEliquis$42$69,37853 claims
Boehringer IngelheimSynjardy, Synjardy Xr, Stiolto Respimat$195$54,52239 claims
GSKTrelegy Ellipta, Arnuity Ellipta$17$41,03762 claims
AstraZenecaSymbicort$120$12,46053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →